Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Diagnostics to Develop Autism Dx With TCAG Markers

NEW YORK (GenomeWeb News) — CombiMatrix’s molecular diagnostics unit will create an array-based test using biomarkers linked to autism that were developed by the Center for Applied Genomics, the company said today.
 
The company said it will use the markers through a partnership with TCAG in a constitutional genetic array test that will be used to screen for autism and “more than 50 disorders.”
 
One version of the test will be available sometime before the end of the month, and another version, to be created with TCAG, that uses the new autism indicators will be available at the end of the year, CombiMatrix said.    
 
Financial terms of the agreement were not released.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.